Oral Drug Delivery for Modified Release Formulations

Preface and Introduction and overview of MR formulations

Part I Understanding of physiology and anatomy - factors influencing drug release and absorption from MR formulations

1. Composition of the GI lumen under fasting and fed conditions

a. Composition of gastric fluids under fasting and fed conditions -
Jens Van Den Abeele and Patrick Augustijns
Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, O&N II, Herestraat 49 - box 921, 3000 Leuven, Belgium

b. Composition of small intestinal fluids under fasting and fed conditions
Edmund Kostewicz
Institute for Pharmaceutical Technology, Goethe University, Max-von-Laure Str. 9, 60439 Frankfurt am Main, Germany

c. Composition of large intestinal fluids under fasting and fed conditions
Christos Reppas and Maria Vertzoni
Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

2. Gastrointestinal transit and hydrodynamics under fasting and fed conditions
Mirko Koziolek
Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany

3. Intestinal Epithelium and Drug Transporters
Karelle Menochet*1, Hugues Chanteux*2, Jamie Henshall1, Jean-Marie Nicolas2, Sara Wright1, Judith van Asperen2 and Anna-Lena Ungell2
1UCB Celltech, Slough, United Kingdom
2UCB Biopharma SPRL, Braine-l'Alleud, Belgium

4. The interplay between drug release and intestinal gut-wall metabolism
Adam S. Darwich1, Oliver J.D. Hatley2, Andres Olivares-Morales1,3, Farzaneh Salem2, Alison Margolskee1, Amin Rostami-Hodjegan1,2
1Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester, Manchester M13 9PT, United Kingdom
2Certara, Blades Enterprise Centre, Sheffield, S2 4SU, United Kingdom
3Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

Part II Design of MR formulations - considerations, mechanisms and technologies

5. Preformulation considerations for design of oral modified-release products
Christel A. S. Bergstroem1 and Rene Holm2
1 Department of Pharmacy, Uppsala University, Uppsala Biomedical Centre P.O. Box 580, SE-751 23 Uppsala, Sweden.
2 Drug Product Development, Janssen Research & Development, Johnson & Johnson, Turnhoutseweg 30, 2430 Beerse, Belgium.

6. The Application of Biopharmaceutics Classification Systems to Modified Release Formulations
James M Butler
Biopharmaceutics, Drug Product Design & Dev
GlaxoSmithKline R&D
Ware UK

7. Technologies and mechanisms for oral modified release by monolithic and multiparticulate delivery systems
Gaia Colombo*, Stavros Politis, Alessandra Rossi
University of Ferrara
44121 FERRARA (Italy)

8. Lipid based Formulations
Joseph P. O'Shea, Caitriona M. O'Driscoll, Brendan T. Griffin
Pharmacodelivery Group, School of Pharmacy, University College Cork, Ireland

9. Strategies for MR formulation development: Mesoporous Silica
Georgios K. Eleftheriadis, Eleni Kontogiannidou, Christina Karavasili, Dimitrios G. Fatouros
Department of Pharmacy, Laboratory of Pharmaceutical Technology, Aristotle University of Thessaloniki, 54124 GR

10. Hot melt extrusion technology for modified release (MR) formulation development
Harpreet Sandhu, Siva Ram Kiran Vaka, Dipen Desai, Paras Jariwala, Aruna Railkar, Wantanee Phuapradit and Navnit Shah
Paras Jariwala, Aruna Railkar, Wantanee Phuapradit
Kashiv Pharma LLC, 995 Route 202/206 Bridgewater, NJ 08807

11. Gattefosse: Strategies for MR formulation development - Lipids
Yvonne Rosiaux, Vincent Jannin and Cecile Morin
Gattefosse SAS - 36 chemin de Genas
69804 Saint Priest France

12. Evonik: Polymethacrylates for Modified Release Formulations
Miriam Robota, Felix Hofmann and Meike Pistner
Meike Pistner
Evonik Nutrition & Care GmbH, Darmstadt, Germany

13. Capsugel - Strategies for Modified Release oral formulation development
Aurelien Sivert1, Randy Wald2, Chris Craig2, Hassan Benameur1
Randy Wald
1Capsugel/Lonza R&D, Strasbourg, France 2Capsugel/Lonza R&D, Bend, Oregon USA

Part III Evaluation of MR formulations

14. Dissolution equipment and hydrodynamic considerations for evaluating MR formulations
Sandra Klein
Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany

15. The role and application of dissolution media for the investigation of modified release formulations
Institute for Pharmaceutical Technology, Goethe University, Max-von-Laue Str. 9, 60439 Frankfurt am Main, Germany

16. Biorelevant dissolution testing to forecast the in vivo performance of modified release formulations
Mirko Koziolek
Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany

17. In vitro dissolution tests for considering dissolution in the lower intestine
Constantinos Markopoulos, Maria Vertzoni
1Faculty of Pharmacy, School of Health Sciences, National & Kapodistrian University of Athens, Greece

18. Preclinical evaluation - animal models to evaluate MR formulations
Rene Holm
Drug Product Development, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium. E-mail: rholm@its.jnj.com

19. In vitro - In vivo correlations for modified release formulations
Ivana Tomic1 and Jean-Michel Cardot2
1Novartis Pharma AG, Technical R&D, Physic Garden 3 - 3.14.49, CH-4002 Base, Switzerland
2Universite Clermont Auvergne MEDIS, CHU Clermont-Ferrand, CIC1405, INSERM, F-63000 Clermont-Ferrand, France

20. Application of the Simcyp Population-Based PBPK Simulator to the Modelling of MR Formulations
Nikunjkumar Patel, Shriram M. Pathak and David B. Turner
Simcyp Ltd (A Certara Company); UK

21. PK-Sim (R) for modeling oral drug delivery of modified release formulations
Donato Teutonico, Michael Block, Lars Kuepfer, Juri Solodenko, Thomas Eissing*, Katrin Coboeken
Michael Block, Lars Kuepfer, Katrin Coboeken
Bayer AG, Clinical Pharmacometrics, Germany

22. Clinical Evaluation - In vivo bioequivalence assessment of MR formulations
Konstantina Soulele, Panos Macheras
Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Athens, Athens 15771, Greece

23. U.S. Regulatory Considerations for Modified Release Products
Hao Zhu, Ramana S. Uppoor, Mehul Mehta
Office of Clinical Pharmacology, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA

24. Regulatory Assessment, European Perspective
Malin Filler and Anders Lindahl

25. Industry perspectives for the evaluation of MR formulations
Irena Tomaszewska and Mark McAllister
Pfizer, Medicinal Sciences, Sandwich, UK

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Química

<p>modified release formulations; oral delivery MR formulations; oral absorption MR; modified release formulations; gastrointestinal physiology; modified release formulations oral absorption; MR formulation evaluation; MR formulation design; MR formulation technologies </p>